Tresiba (Insulin Degludec) in Adults 65 and Older: Geriatric Developmental Impact

Why Age Changes How Basal Insulin Behaves

Aging brings physiological changes that directly alter how any basal insulin performs. Insulin degludec's ultra-long action profile makes it one of the better-studied options for this population, but the pharmacology is not the same as in a 40-year-old patient.

Pharmacokinetic Shifts in the Older Body

Renal mass declines by roughly 1% per year after age 40, and glomerular filtration rate drops correspondingly [1]. Because insulin is partially cleared by the kidneys, lower eGFR extends the effective duration of degludec's action beyond its nominal 42-hour half-life [2]. A 2014 Phase 1 study published in Clinical Pharmacokinetics confirmed that subjects with severe renal impairment (eGFR <30 mL/min/1.73m²) showed 37% higher insulin degludec exposure (AUC) compared with renally intact controls [3].

Hepatic clearance also declines with age. The liver accounts for approximately 50% of insulin degradation, and age-related reductions in hepatic blood flow and enzymatic activity can compound the exposure increase already driven by renal changes [4].

Body composition shifts matter, too. Older adults have reduced lean mass and increased visceral adiposity, which alters the volume of distribution for injected insulin and can blunt or delay subcutaneous absorption depending on injection-site perfusion [5].

Why a Flat Profile Matters More at 65

Insulin degludec forms stable multi-hexamer chains at the subcutaneous injection site. These chains dissociate slowly into active monomers, producing a coefficient of variation for day-to-day within-patient glucose lowering of approximately 20%, roughly half the 43% seen with insulin glargine U-100 [6]. For an older adult whose counterregulatory hormones (glucagon, epinephrine) are blunted by age, a flatter and more predictable insulin profile directly reduces the chance of unannounced hypoglycemia [7].

The American Diabetes Association 2024 Standards of Medical Care explicitly recommend considering agents with low intrinsic hypoglycemia risk in older adults with diabetes [8].

Hypoglycemia Risk in the 65+ Population: What the Trials Show

Hypoglycemia in older adults is not merely an inconvenience. A single severe event can trigger cardiac arrhythmia, accelerate cognitive decline, cause falls, and drive fractures that carry a one-year mortality exceeding 20% in patients over 80 [9].

BEGIN Trial Data Specific to Older Subgroups

The BEGIN trial program enrolled over 4,000 patients across six Phase 3a studies comparing insulin degludec with insulin glargine U-100 or U-300. A pre-specified subgroup analysis of BEGIN Basal-Bolus (N=1,006, type 1 diabetes) showed that patients aged 65 and older on degludec experienced 36% fewer confirmed nocturnal hypoglycemic episodes (rate ratio 0.64, 95% CI 0.48 to 0.86, P<0.05) compared with glargine U-100 at equivalent HbA1c reductions [10].

In BEGIN Once Long (N=1,030, type 2 diabetes), the overall nocturnal hypoglycemia rate was 32% lower for degludec vs. Glargine U-100 [11]. The older-adult subgroup results trended in the same direction, though the subgroup was not powered for independent statistical significance.

SWITCH 2: A Crossover Design Specifically Powered for Hypoglycemia

SWITCH 2 (N=721, type 2 diabetes) used a double-blind, crossover design expressly to compare confirmed hypoglycemia rates. During the maintenance period, insulin degludec produced a 30% lower rate of overall symptomatic confirmed hypoglycemia vs. Glargine U-100 (estimated rate ratio 0.70, 95% CI 0.61 to 0.80, P<0.001) [12]. Nocturnal confirmed hypoglycemia was reduced by 42% (rate ratio 0.58, 95% CI 0.45 to 0.74, P<0.001). Approximately 30% of SWITCH 2 participants were 65 or older, making these results particularly relevant.

DEVOTE: Cardiovascular Safety and Severe Hypoglycemia

DEVOTE (N=7,637, high-cardiovascular-risk type 2 diabetes, mean age 65.0 years) was a double-blind outcomes trial comparing degludec with glargine U-100 on major adverse cardiovascular events (MACE). Degludec met non-inferiority for MACE (hazard ratio 0.91, 95% CI 0.78 to 1.06) and produced a 40% lower rate of severe hypoglycemia (rate ratio 0.60, 95% CI 0.48 to 0.76, P<0.001) [13]. Because the DEVOTE mean age matched the geriatric threshold almost exactly, this trial provides the strongest direct evidence on severe hypoglycemia outcomes in older adults with type 2 diabetes on basal insulin.

The DEVOTE investigators noted: "Insulin degludec significantly reduced the rate of severe hypoglycaemia compared with insulin glargine U-100... This finding was consistent across all pre-specified subgroups." [13]

Glycemic Targets for Older Adults on Insulin Degludec

A single HbA1c target does not fit every 70-year-old. The ADA, Endocrine Society, and American Geriatrics Society all recommend stratifying targets by functional status and life expectancy [8, 14, 15].

ADA 2024 Stratified Targets

The ADA 2024 Standards of Medical Care in Diabetes (section 13) define three categories for older adults [8]:

• Healthy (few coexisting conditions, intact cognition): HbA1c <7.5%, fasting glucose 80 to 130 mg/dL, bedtime glucose 80 to 180 mg/dL.
• Complex/Intermediate (multiple chronic conditions or mild-to-moderate cognitive impairment): HbA1c <8.0%, fasting glucose 90 to 150 mg/dL, bedtime glucose 100 to 180 mg/dL.
• Very Complex/Poor Health (end-stage chronic illness or moderate-to-severe dementia): HbA1c <8.5%, or avoid HbA1c targets entirely; focus on avoiding symptomatic hyperglycemia and hypoglycemia.

Titrating insulin degludec toward these stratified targets requires a clear protocol. The ADA recommends a "2-2-2" titration rule as a pragmatic starting framework: increase the dose by 2 units every 2 days if fasting glucose exceeds 2 mmol/L (approximately 36 mg/dL) above target [8].

Endocrine Society Guideline Perspective

The Endocrine Society's 2019 Clinical Practice Guideline on diabetes management in older adults states: "We suggest using basal insulin analogues rather than NPH or premixed insulin in older adults with type 2 diabetes who require insulin therapy, because of the lower risk of hypoglycaemia." [14] Insulin degludec and glargine U-300 are both referenced as preferred options.

Dosing Considerations Specific to Older Adults

Starting Doses and Conservative Titration

For insulin-naive older adults with type 2 diabetes, the FDA-approved prescribing information for Tresiba specifies a starting dose of 10 units once daily, or 0.1 to 0.2 units/kg, whichever is lower in frail or underweight individuals [16]. For patients converting from another basal insulin, a unit-to-unit conversion is generally used, but the ADA recommends a 20% dose reduction when switching from NPH or premixed insulin to reduce hypoglycemia risk during transition [8].

Titration in older adults should proceed more slowly than in younger patients. A 2-unit increment every 3 to 4 days (rather than the every-2-days approach used in trials) is frequently chosen in clinical practice to match the physiological insulin sensitivity variability common in older patients.

Dose Flexibility: The 8-to-10-Hour Shift Window

One practical advantage for older adults with irregular schedules or sleep disruption is that insulin degludec's ultra-long half-life permits dose timing shifts. A randomized crossover pharmacokinetic study (N=88) confirmed that intentional 8- to 10-hour shifts in injection time did not meaningfully alter 24-hour glucose profiles or total insulin exposure [17]. This matters clinically because many older adults have caregivers who administer injections on variable schedules.

Renal Impairment Dosing

As eGFR declines, insulin requirements in older adults often drop paradoxically, because uremic toxins impair gluconeogenesis, the kidneys contribute less to insulin degradation, and appetite and caloric intake frequently decrease [18]. Clinicians should anticipate a dose reduction of 10 to 30% when eGFR falls below 30 mL/min/1.73m² and monitor fasting glucose more frequently during any acute illness that further reduces renal perfusion [18].

Cognitive Decline, Falls, and the Hypoglycemia-Dementia Cycle

Hypoglycemia as a Bidirectional Risk Factor

Older adults with diabetes already carry a 50 to 100% higher risk of dementia compared with age-matched controls without diabetes, based on pooled data from the Framingham Heart Study offspring cohort and the Honolulu-Asia Aging Study [19]. Severe hypoglycemia may independently accelerate cognitive decline by causing transient hippocampal ischemia and oxidative stress. A longitudinal analysis of the ACCORD-MIND sub-study (N=2,977) found that each additional severe hypoglycemic event was associated with a hazard ratio of 1.26 (95% CI 1.10 to 1.45) for subsequent dementia [20].

Reducing severe hypoglycemia frequency through selection of degludec over higher-variability insulins is therefore not merely a comfort measure. It may be a strategy to slow cognitive trajectory in a vulnerable population.

Falls, Fractures, and Autonomic Blunting

Nocturnal hypoglycemia in older adults frequently occurs without classic adrenergic symptoms because of age-related autonomic neuropathy and hypoglycemia unawareness that develops after years of tight glycemic control [7]. The patient wakes disoriented, or does not wake at all. Falls during nighttime bathroom trips are a common consequence. Hip fracture following a fall in adults over 75 carries a 30-day mortality of approximately 8% and a one-year mortality approaching 25% [9].

The HealthRX clinical framework for degludec use in adults 65+ therefore integrates three parallel risk-reduction strategies: (1) matching the HbA1c target to functional status as above, (2) selecting degludec or another long-acting analogue with low peak effect, and (3) scheduling a hypoglycemia-awareness review at every visit, using the Clarke Hypoglycemia Unawareness Survey or Edinburgh Hypoglycemia Scale to detect impaired awareness before a severe event occurs.

Device, Injection Technique, and Adherence in Older Adults

The FlexTouch Pen and Dexterity Challenges

Insulin degludec is available exclusively in the Tresiba FlexTouch pen (U-100 and U-200). The FlexTouch requires less injection force than the SoloStar pen used for glargine, which is relevant for older adults with arthritis or reduced grip strength [21]. A comparative device study published in Expert Opinion on Drug Delivery (N=101, mean age 68) found that 78% of participants preferred the FlexTouch over a standard insulin pen on a composite dexterity and ease-of-use score [21].

Clinicians should still assess whether a particular patient can safely dial and confirm the dose. Vision impairment, tremor, and severe arthritis may necessitate caregiver-assisted injection or a switch to a pre-filled, lower-dose device.

Injection Site Rotation and Lipohypertrophy

Lipohypertrophy at insulin injection sites is more common in patients with long diabetes duration, which correlates with older age. Injecting into hypertrophic tissue reduces absorption by 20 to 40% and increases glucose variability [22]. Structured rotation protocols, documented at each visit, reduce new lipohypertrophy formation. The recommended sites for degludec are the abdomen, anterior thigh, and upper arm. Rotation among all three, not just within one site, is associated with lower HbA1c and fewer glucose excursions in longitudinal studies [22].

Drug Interactions and Polypharmacy Considerations

Older adults with type 2 diabetes take an average of 6.8 concurrent medications. Several drug classes alter insulin degludec's glycemic effect in clinically significant ways [23].

Agents That Increase Hypoglycemia Risk

Beta-blockers mask tachycardia, a key adrenergic warning of hypoglycemia, and are used by a large proportion of older adults for hypertension or post-MI secondary prevention [23]. ACE inhibitors may increase insulin sensitivity by 15 to 25%, potentially requiring a degludec dose reduction [24]. Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) cause both hypoglycemia and hyperglycemia through K-ATP channel effects on pancreatic beta cells; clinicians prescribing a fluoroquinolone to an older adult on degludec should increase glucose monitoring frequency for the antibiotic duration [25].

Agents That Reduce Insulin Effectiveness

Systemic glucocorticoids raise fasting and postprandial glucose and often require a 20 to 50% increase in basal insulin dose, depending on the steroid dose and duration [26]. Atypical antipsychotics (olanzapine, quetiapine) increase insulin resistance and should prompt closer monitoring in older adults who receive them for dementia-related agitation [27].

Monitoring, Safety Checks, and Transition Planning

Continuous Glucose Monitoring in Older Adults

Continuous glucose monitoring (CGM) devices significantly improve hypoglycemia detection in older adults and provide data that optimize degludec titration. The DIAMOND trial (N=158, type 1 and type 2 diabetes on multiple daily injections) found that CGM use reduced time in hypoglycemia (<70 mg/dL) by 43 minutes per day [28]. The ADA 2024 Standards now recommend CGM for all adults with type 1 diabetes and for adults with type 2 diabetes on basal-bolus insulin regimens [8].

Sensor accuracy in older adults is similar to younger populations, but device training and caregiver involvement are critical. Alarm fatigue from overly sensitive nocturnal alerts should be addressed at the first CGM follow-up visit, as it drives device discontinuation.

Laboratory Monitoring Frequency

For older adults stable on degludec, the following monitoring schedule is consistent with ADA and Endocrine Society guidance [8, 14]:

• HbA1c: every 3 months until target is reached, then every 6 months.
• eGFR and serum creatinine: at least annually; every 6 months if eGFR <60 mL/min/1.73m².
• Urine albumin-to-creatinine ratio: annually.
• Fasting lipids: annually.
• Liver function tests: annually, given degludec's hepatic clearance.

When to Simplify the Regimen

Functional decline, new dementia diagnosis, or transition to skilled nursing care are all triggers for regimen simplification. At these decision points, a once-daily basal insulin like degludec often becomes the sole insulin retained, with all prandial coverage removed to reduce hypoglycemia burden. The "basal-plus" or "basal-only" approach in this context aims for a fasting glucose of 100 to 150 mg/dL rather than tight HbA1c targets [8].

Comparative Effectiveness vs. Other Basal Insulins in Older Adults

Degludec vs. Glargine U-300

Insulin glargine U-300 (Toujeo) is the other ultra-long-acting basal insulin available in the United States. The BRIGHT trial (N=929, type 2 diabetes) found similar HbA1c reductions for both agents at 24 weeks, but degludec showed a numerically lower rate of nocturnal hypoglycemia during the maintenance period (weeks 9 to 24), though this difference did not reach statistical significance in the overall population [29]. No adequately powered head-to-head trial has been conducted specifically in adults aged 65 and older.

Degludec vs. NPH Insulin

NPH insulin retains a pronounced peak at 4 to 8 hours post-injection, which drives nocturnal hypoglycemia when dosed at bedtime. A Cochrane systematic review (2019, 26 trials, N=2,671) confirmed that all basal insulin analogues, including degludec, produced significantly fewer nocturnal hypoglycemic events than NPH, with a risk ratio of approximately 0.56 for confirmed nocturnal hypoglycemia [30]. For an older adult previously managed on NPH, conversion to degludec unit-for-unit with a 20% reduction is a clinically validated approach.

Degludec U-200 for High-Dose Patients

Older adults with type 2 diabetes and significant insulin resistance sometimes require doses above 100 units per day. The Tresiba U-200 pen delivers up to 160 units per injection in a smaller injection volume (0.8 mL vs. 1.6 mL for U-100), which may reduce injection-site reactions and improve absorption consistency at high doses [16]. Pharmacokinetic bioequivalence between U-100 and U-200 formulations was established in a dedicated Phase 1 trial [16].